Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Signing Ceremony of the "PARAMED Project"

 
Signing Ceremony of the "PARAMED Project": A Vital Reinforcement of the Public Health Sector in Lebanon
 

Under the patronage of H.E. Dr. Firass El Abiad, Mnister of Public Health, and in the presence of a delegation from the French Ministry of Health, an official signing ceremony for the "Project for Supporting the Healthcare Personnel Skills in the Public Sector in Lebanon (PARAMED)" took place in the conference room of the Ministry of Public Health (MOPH) in Jnah.  .

This project, co-financed by Agence Française de Developpement (AFD) and the IF! Foundation, and implemented by the European Institute for Cooperation and Development (IECD), aims to substantially strengthen the skills of healthcare professionals within Lebanon's public health structures.

In his speech, the Minister of Public Health, Dr. Firas El Abiad, emphasized: "The importance of this program lies in its expansion to include 12 public hospitals, after initially starting with four hospitals, with the aim of training healthcare professionals so they can provide the necessary services to our citizens, especially the most vulnerable segments of Lebanese society. This program is funded by the French Development Agency to the tune of six million euros and is implemented by the European Institute for Cooperation and Development in Lebanon." Minister Abiad continued by stating that: “This program would not have been possible without the support provided by France to Lebanon, particularly through the French Development Agency (AFD), which supports several projects in the health and education sectors. What is remarkable about this program is that it brings together the health and education sectors, with the goal of providing better healthcare services to all people on Lebanese territory.”

Mrs. Catherine Bonnaud, Country Director and Regional Director of AFD, declared that by investing in training and professional development of health workers, we strengthen not only individual capabilities, but also the resilience and effectiveness of the health system as a whole. This is a long-term investment in the health and well-being of all Lebanese citizens.

In a context of crisis affecting the Lebanese healthcare system, the PARAMED project represents a crucial initiative to improve the quality of care provided to the most vulnerable populations and facilitate access to it. The project includes, among other objectives, the establishment of training centers in 12 public hospitals and the implementation of ongoing training and refresher programs for recent graduates and existing hospital staff.
 
Mr. Vianney Basse, Director for Lebanon and the Middle East at IECD, emphasized the quality of the trust-based relationship between the Minister of Health, AFD, and IECD, and that this partnership is fully aligned with the Ministry’s 2030 Strategy. He recalled that IECD, whose mission is to support youth through vocational training projects, will strengthen its involvement in the health sector through PARAMED.

By strengthening the capacities of health professionals and promoting the employability of young men and women in the field of nursing, the PARAMED project aims to reach 4,200 healthcare workers and approximately 3 million patients. In doing so, it will help reduce gaps and improve the quality of healthcare in Lebanon.
    ...
    8
    ...
ATC Name B/G Ingredients Dosage Form Price
H02AB02 DEXAMED G Dexamethasone - 8mg/2ml 8mg/2ml Injectable solution 486,471 L.L
H02AB02 DEXAMEDIS FORT G Dexamethasone Phosphate - 8mg/2ml 8mg/2ml Injectable solution 43,003 L.L
H02AB02 DEXAMETHASONE PANPHARMA G Dexamethasone (sodium phosphate) - 8mg/2ml 8mg/2ml Injectable solution 1,076,418 L.L
H02AB02 DEXAMETHASONE SODIUM PHOSPHATE INJECTION USP G Dexamethasone (sodium phosphate) - 8mg/2ml 8mg/2ml Injectable solution 358,806 L.L
H02AB02 DEXAMETHASONE SODIUM PHOSPHATE USP - EIPICO G Dexamethasone (sodium phosphate) - 8mg/2ml 8mg/2ml Injectable solution 185,450 L.L
H02AB02 DEXASINA G Dexamethasone Phosphate - 8mg/2ml 8mg/2ml Injectable solution 3,471,145 L.L
H02AB02 DECADRON B Dexamethasone - 0.5mg 0.5mg Tablet, scored 393,218 L.L
H02AB02 DEXAMETHASONE MEDIS G Dexamethasone Phosphate - 4mg/1ml 4mg/1ml Injectable solution 1,154,361 L.L
H02AB02 DEXAMETHASONE NOVUMGEN G Dexamethasone - 4mg 4mg Tablet 8,455,824 L.L
H02AB04 DEPO MEDROL B Methylprednisolone acetate - 40mg/ml 40mg/ml Injectable suspension 182,763 L.L
H02AB04 DEPO MEDROL B Methylprednisolone acetate - 80mg/2ml 80mg/2ml Injectable suspension 365,525 L.L
H02AB13 DEFAL B Deflazacort - 6mg 6mg Tablet 415,247 L.L
H02AB13 DEFAL B Deflazacort - 30mg 30mg Tablet 635,638 L.L
J01AA02 DOXY 50 G Doxycycline (hyclate) - 50mg 50mg Tablet, coated 306,396 L.L
J01AA02 DOXY 100 G Doxycycline (hyclate) - 100mg 100mg Tablet, coated 788,836 L.L
J01AA02 DOXYKEY G Doxycycline (hyclate) - 100mg 100mg Capsule 174,700 L.L
J01AA02 DOXYLAG G Doxycycline (hyclate) - 100mg 100mg Capsule 174,700 L.L
J01FF01 DALACIN-C B Clindamycin HCl - 150mg 150mg Capsule 287,582 L.L
J01FF01 DALACIN-C B Clindamycin HCl - 300mg 300mg Capsule 478,408 L.L
J01FF01 DANALLI G Clindamycin HCl - 300mg 300mg Capsule 267,425 L.L
J01RA DUREL FORTE G Metronidazole - 250mg, Spiramycin - 1.5MIU Tablet, coated 602,041 L.L
J02AC01 DIFLUCAN B Fluconazole - 50mg 50mg Capsule 622,199 L.L
J02AC01 DIFLUCAN B Fluconazole - 150mg 150mg Capsule 286,238 L.L
J04AB03 DIARENTIS B Rifamycin sodium - 200mg 200mg Tablet, extended release 1,100,671 L.L
J05AR24 DELSTRIGO B Lamivudine - 300mg, Tenofovir disoproxil - 300mg, Doravirine - 100mg Tablet, film coated 48,879,793 L.L
J05AR27 DOLUTEGRAVIR/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE G Lamivudine - 300mg, Tenofovir disoproxil fumarate - 300mg, Dolutegravir - 50mg Tablet 54,836,160 L.L
J07CA11 DIPHTHERIA, TETANUS,PERTUSSIS, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE B Diphteria Toxoid1 - ?25Lf (?30IU)/0.5ml, Tetanus toxoid1 - ?2.5Lf (?40IU)/0.5ml, Bordetella pertussis (Whole cell) - ?16OU (?4.0IU)/0.5ml, HBs Antigen (r DNA)1 - ?10mcg/0.5ml, H. Influenza type b, purified capsular polysaccharide2 - 10mcg/0.5ml, 1 adsorbed on aluminium phosphate, Al+++ - ?1.25mg , 2 conjugated to tetanos toxoid carrier protein - Injectable suspension 1,515,854 L.L
L01AX04 DACARBAZINE MEDAC G Dacarbazine - 200mg 200mg Injectable powder for solution 15,866,076 L.L
L01AX04 DACARBAZINE MEDAC G Dacarbazine - 1,000mg 1,000mg Injectable powder for solution 5,411,654 L.L
L01BC06 DIROGIT G Capecitabine - 500mg 500mg Tablet, film coated 11,330,804 L.L
    ...
    8
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026